Accession Number: | 0001209191-20-010499 |
Date: | 2020-02-14 |
Issuer: | ODONATE THERAPEUTICS, INC. (ODT) |
Original Submission Date: |
HEARNE MICHAEL S
C/O ODONATE THERAPEUTICS, INC.
4747 EXECUTIVE DRIVE, SUITE 510
SAN DIEGO, CA 92121
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-02-14 | A | 21 | a | $26.73 | 1,404 | direct | ||
COMMON STOCK | 2020-02-14 | 0 | $0.00 | 14,075,269 f2 | indirect | f2 |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 31.45 | 2020-02-14 | deemed execution date | A | 21 (a) | 2030-02-14 | common stock 21 | $31.45 | 21 | direct |
ID | footnote |
---|---|
f1 | these shares were acquired on 02/14/2020 through the odonate therapeutics, inc. 2017 employee stock purchase plan in a transaction that was exempt under both rule 16b-3(d) and rule 16b-3(c). |
f2 | the securities are beneficially owned by tang capital partners, lp ("tcp"). tang capital management, llc ("tcm") is the general partner of tcp. the shares reported as beneficially owned by tcp include a total of 154,285 shares of common stock that are held of record by odonate holdings, llc ("holdings"). holdings has granted a proxy to tcp giving tcp the sole authority to vote such shares. michael hearne is the chief financial officer of odonate therapeutics, inc., as well as chief financial officer of tcm. mr. hearne has a pecuniary interest in a portion of the shares beneficially held by tcp. |
f3 | the stock options vest and become exercisable as follows: (i) 50% on the date of u.s. food and drug administration ("fda") approval of tesetaxel, odonate's investigational product; (ii) 25% on the first anniversary of fda approval of tesetaxel; and (iii) 25% on the second anniversary of fda approval of tesetaxel. vesting is subject to the reporting person's continued service to the issuer through each vesting date. |